Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
Currently, enhancement of cholinergic neurotransmission via cholinesterase inhibitors represents the main available approach to treat cognitive and behavioural symptoms of the early as well as late stages of Alzheimer's disease.
-
Alzheimer's disease (AD) is the most common cause of dementia.
-
Aducanumab is a monoclonal antibody selective for amyloid β (Aβ) aggregates.
-
Alzheimer's disease (AD) is the most prevalent form of age-related dementia in the world, and its main pathological features consist of amyloid-β (Aβ) plaque deposits and neurofibrillary tangles formed by hyperphosphorylated tau protein.
-
Selecting the right dose is a significant challenge in designing clinical development programs, especially for slowly progressing diseases lacking predictive biomarkers of efficacy that may require long-term treatment to assess clinical benefit.
-
Aducanumab (Aduhelm) is approved in the United States for the treatment of patients with mild cognitive impairment due to Alzheimer's disease or mild AD dementia.
-
Scientific advances over the last four decades have steadily infused the Alzheimer's disease (AD) field with great optimism that therapies targeting Aβ, amyloid, tau, and innate immune activation states in the brain would provide disease modification.
-
Alzheimer's disease (AD) is the most common cause for dementia worldwide.
-
Alzheimer's disease (AD) is a progressive neurodegenerative disease and accounts for most cases of dementia.
-
Alzheimer's disease (AD) is a neurodegenerative old age disease that is complex, multifactorial, unalterable, and progressive in nature.
-
Aducanumab has been approved by the US Food and Drug Administration for treatment of Alzheimer's disease (AD).
-
Donanemab was generally well tolerated up to 10 mg/kg.
-
Aducanumab recently underwent two large phase III clinical trials that were stopped prematurely by the sponsor Biogen.
-
43/100
Acute symptoms included headache and encephalopathy, and magnetic resonance imaging revealed ARIA-E and ARIA-H. Malignant hypertension and epileptiform activity were treated with nicardipine and levetiracetam.
-
Individuals experiencing complications, such as worsening symptoms and functional impairment when a medication dose wears off ("off periods"), medication-resistant tremor, and dyskinesias, benefit from advanced treatments such as therapy with levodopa-carbidopa enteral suspension or deep brain stimulation.
-
43/100
Among persons diagnosed with ADRD or related symptoms, 33.3% used an approved drug over the study period.
-
Solanezumab produced statistically significant increases in CSF total Aβ isoforms versus placebo, which correlated with CSF solanezumab concentration.
-
Efforts to develop new therapies to combat Alzheimer's disease suffer from extraordinarily high failure rates that make it difficult to justify continued investment in the field.
-
There were nine inclusion/exclusion criteria that were used in more than half of the late life depression AETs: minimum severity on a symptom severity scale (100.0%), significant suicidal ideation (77.8%), psychotic features during the current episode of depression or history of a psychotic disorder (94.4%), history of bipolar disorder (77.8%), diagnosis of alcohol or drug abuse or dependence (83.3%), presence of a comorbid nondepressive, nonsubstance use Axis I disorder (55.6%), episode duration too short (66.7%), and an insufficient score on a cognitive screen (88.3%) or the presence of a cognitive disorder (55.6%).
-
Aducanumab (BIIB037) is a human monoclonal antibody selective for aggregated forms of beta-amyloid peptide being investigated as a disease-modifying treatment for AD.
-
PRE2DUP method gives highly accurate drug use periods for most drug classes, especially those meant for long-term use.
-
Ranolazine and metformin may be frequently co‐administered in subjects with chronic angina and co‐morbid type 2 diabetes mellitus (T2DM).
-
The Clinicaltrials.gov database demonstrates that relatively few clinical trials are undertaken for AD therapeutics, considering the magnitude of the problem.
-
Traumatic brain injury (TBI), either as an isolated injury or in conjunction with other injuries, is an increasingly common event.
-
We describe a hitherto unknown feature for 27 small drug-like molecules, namely functional inhibition of acid sphingomyelinase (ASM).
From across this topic
9 of the 902 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.
- Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease
- Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial
- Glutamate as a therapeutic target in psychiatric disorders
- Balancing benefit and risk in early Alzheimer's disease: the European Medicines Agency (EMA) assessment of lecanemab and donanemab
- Long-term use of metformin and Alzheimer's disease: beneficial or detrimental effects
- Population pharmacokinetics and exposure-response analyses of safety (ARIA-E and isolated ARIA-H) of lecanemab in subjects with early Alzheimer's disease
- Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline
- Anti-Amyloid Therapies for Alzheimer's Disease and the Amyloid Cascade Hypothesis
- Identifying and Treating Insomnia in Patients Living With Alzheimer's Disease